Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-01-05 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
审计与风险控制委员会关于对北京医洋科技有限公司股改项目所涉关联交易的审核意见
Audit Report / Information Classification · 95% confidence The document is an audit committee opinion on a related party transaction involving a share reform project of a company. It references regulatory rules and company bylaws, and provides an audit committee's review and approval to submit the matter to the board. The document is short (682 characters) and focuses on audit committee's opinion rather than a full audit report or financial statements. It is not a full Annual Report or standalone Audit Report but rather an audit-related opinion on a specific transaction. This fits best under Audit Report / Information (AR) category, which includes audit reports and applied accounting principles related to specific matters, excluding full annual reports.
2016-01-05 Chinese
关于下属公司北京医洋科技有限公司股改暨出售股权及与关联方共同投资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving the sale and capital increase of a subsidiary company, Beijing Yiyang Technology Co., Ltd. It includes specifics about the transaction parties, shareholding changes, investment amounts, legal agreements, and approvals required. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about a capital and shareholding change involving related parties. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a formal disclosure of a capital/financing update and related-party transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2016-01-05 Chinese
关于召开2016年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2016 first extraordinary general meeting of shareholders for Kunming Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and proxy authorization. The document does not contain financial statements or detailed financial analysis but is an announcement related to a shareholders' meeting. It specifically notifies shareholders about the meeting and voting procedures, which fits the definition of AGM Information (AGM-R). The document length is 2771 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, the classification is AGM Information (AGM-R).
2016-01-05 Chinese
独立董事关于北京医洋科技有限公司股改项目的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding a share reform project of Beijing Yiyang Technology Co., Ltd. It references regulatory guidelines for independent directors and discusses the fairness and compliance of a related party transaction and shareholding changes. The document is a formal opinion letter rather than a financial report, earnings release, or announcement of voting results. It does not contain financial statements or detailed financial data. It is not a report publication announcement either, as it contains substantive content and opinion. The document fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related opinion document that does not fit other specific categories.
2016-01-05 Chinese
独立董事关于北京医洋科技有限公司股改项目所涉关联交易的事前认可声明
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding a related party transaction in a share reform project of a company. It references regulatory guidelines for independent directors and provides an approval statement. The document is short (612 characters) and does not contain financial statements or detailed financial data. It is a declaration or approval related to governance and compliance rather than a full report or announcement of financial results. This fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and governance-related statements that do not fit other specific categories.
2016-01-05 Chinese
八届五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the company's eighth board meeting, including approval of a share reform plan for a subsidiary and the proposal to convene an extraordinary shareholders' meeting. The document includes voting results and mentions that one agenda item requires shareholder approval. There is no financial data, audit information, or report content. It is an announcement of board decisions, which fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing.
2016-01-05 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.